Local xenogeneic graft-vs-host reaction: a practical assessment of T cell function among cancer patients.
The local xenogeneic graft-vs-host reaction (XGVHR) was used as a practical bioassay to assess T lymphocyte function and immunocompetence among cancer patients. Positive XGVHR was found in 99.5% of normal donors, 70% of cancer patients with early stage disease, and 30% of cancer patients with metastatic disease (p less than 0.001). A minimum of 4.5 x 10(6) immunocompetent T lymphocytes are necessary in order to elicit a positive XGVHR. Negative reactions among cancer patients are characterized by the lack of edema fluid accumulation and the appearance of the most basophils at the test site. This suggests that insufficient amounts of lymphokines are being released by the incompetent T lymphocytes, whereas the host is capable of mounting a rejection reaction as evidenced by the appearance of the basophils. Preliminary evidence suggests that the immunologic defect detected by the XGVHR cannot be corrected by monocyte depletion. The identification of putative suppressor T cell subsets may bear immunotherapeutic implications in the future.
D000818:Animals; D004306:Dose-Response Relationship, Immunologic; D006087:Graft vs Host Reaction; D006801:Humans; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000145:classification; D008222:Lymphokines / Q000494:pharmacology; D008297:Male; D009367:Neoplasm Staging; D009369:Neoplasms / Q000276:immunology*; D051381:Rats; D011917:Rats, Inbred Lew; D012867:Skin / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology*; D014183:Transplantation, Heterologous
D008222:Lymphokines